Table 1.
Characteristics of the patients according to pathological response.
| Factors | All patients | MPR | non-MPR | p value | N+# | N-* | p value |
|---|---|---|---|---|---|---|---|
| Sex — no. (%) | 0.259 | 0.881 | |||||
| Male | 54 | 35 | 19 | 14 | 40 | ||
| Female | 7 | 3 | 4 | 2 | 5 | ||
| Age — yr | |||||||
| Mean ± SD | 61.10 ± 7.99 | 61.43 ± 8.53 | 60.89 ± 7.75 | 58.76 ± 8.77 | 61.78 ± 7.68 | ||
| Histologic subtype | 0.029 | 0.205 | |||||
| SCC$ | 42 | 30 | 12 | 9 | 33 | ||
| non-SCC& | 19 | 8 | 11 | 7 | 12 | ||
| TNM Stage —no. (%) | 0.045 | 0.01 | |||||
| IIA | 5 | 4 | 1 | 0 | 5 | ||
| IIB | 8 | 6 | 2 | 2 | 6 | ||
| IIIA | 36 | 25 | 11 | 7 | 29 | ||
| IIIB | 10 | 2 | 8 | 7 | 3 | ||
| IIIC | 2 | 1 | 1 | 0 | 2 | ||
| Smoking status —no. (%) | 0.237 | 0.595 | |||||
| Never | 16 | 8 | 8 | 5 | 11 | ||
| Former or current | 45 | 30 | 15 | 11 | 34 | ||
| PD-L1 (TPS) | 0.055 | 0.36 | |||||
| <50% | 24 | 17 | 7 | 4 | 20 | ||
| ≥50% | 14 | 11 | 3 | 4 | 10 | ||
| unknown | 23 | 10 | 13 | 8 | 15 | ||
| cycles pre-operation | 0.711 | 0.802 | |||||
| 2 | 43 | 28 | 15 | 12 | 31 | ||
| 3 | 15 | 8 | 7 | 3 | 12 | ||
| 4 | 3 | 2 | 1 | 1 | 2 | ||
| cycles post-operation | 0.972 | 0.048 | |||||
| ≤5 | 29 | 18 | 11 | 11 | 18 | ||
| >5 | 32 | 20 | 12 | 5 | 27 |
N+#, lymph node metastasis based on postoperative pathology; N-*, no lymph node metastasis based on postoperative pathology; SCC$, squamous cell carcinomas; non-SCC&, non-squamous cell carcinomas. MPR, major pathological response; pCR, complete pathological response, PD-L1, programmed-death ligand 1; TPS, tumor-proportion score.